Ravi Salgia

List of Publications by Citations

384 papers	26,527 citations	80 h-index	155 g-index
415 ext. papers	30,021 ext. citations	6.2 avg, IF	6.88 L-index

#	Paper	IF	Citations
384	Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *New England Journal of Medicine*, **2010**, 363, 1693-703	59.2	3577
383	Crizotinib in ROS1-rearranged non-small-cell lung cancer. *New England Journal of Medicine*, **2014**, 371, 1963-71	59.2	1267
382	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncology, The*, **2012**, 13, 1011-9	21.7	983
381	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncology, The*, **2011**, 12, 1004-12	21.7	732
380	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations **2018**, 6, 8		606
379	Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. *Cancer Research*, **2005**, 65, 1479-88	10.1	470
378	Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. *Cancer Discovery*, **2015**, 5, 850-9	24.4	460
377	c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. *Cancer Letters*, **2005**, 225, 1-26	9.9	440
376	The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, 33-8	1.5	438
375	Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. *Journal of Clinical Oncology*, **2011**, 29, 2660-6	2.2	433
374	c-Met: structure, functions and potential for therapeutic inhibition. *Cancer and Metastasis Reviews*, **2003**, 22, 309-25	9.6	379
373	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. *Journal of Clinical Oncology*, **2011**, 29, 4803-10	2.2	364
372	Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer. *FASEB Journal*, **2012**, 26, 2175-86	0.9	359
371	Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. *Journal of Thoracic Oncology*, **2011**, 6, 942-6	8.9	354
370	Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. *Cytokine and Growth Factor Reviews*, **2002**, 13, 41-59	17.9	341
369	Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. *Journal of Clinical Oncology*, **2015**, 33, 4284-92	2.2	323
368	c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. *Cancer Research*, **2003**, 63, 6272-81	10.1	311

367	The role of ephrins and Eph receptors in cancer. *Cytokine and Growth Factor Reviews*, **2004**, 15, 419-33	17.9	272
366	The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. *Journal of Biological Chemistry*, **2000**, 275, 24273-8	5.4	248
365	Expression and mutational analysis of MET in human solid cancers. *Genes Chromosomes and Cancer*, **2008**, 47, 1025-37	5	246
364	Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. *Clinical Cancer Research*, **2015**, 21, 870-81	12.9	242
363	Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. *Journal of Clinical Oncology*, **2003**, 21, 624-30	2.2	242
362	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. *Lancet Oncology, The*, **2016**, 17, 1683-1696	21.7	224
361	The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. *Cancer Research*, **2009**, 69, 3021-31	10.1	220
360	Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR/ABL. *Journal of Biological Chemistry*, **1995**, 270, 5039-47	5.4	220
359	c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. *Cancer Research*, **2007**, 67, 1670-9	10.1	217
358	Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. *Oncogene*, **2000**, 19, 3521-8	9.2	208
357	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. *Clinical Cancer Research*, **2013**, 19, 3068-77	12.9	192
356	Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. *Blood*, **2005**, 105, 1717-23	2.2	187
355	The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. *Anesthesia and Analgesia*, **2011**, 112, 558-67	3.9	183
354	Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. *Cancer Research*, **2002**, 62, 6304-11	10.1	180
353	Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. *Cancer Research*, **2006**, 66, 352-61	10.1	171
352	Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. *Clinical Cancer Research*, **2002**, 8, 620-7	12.9	167
351	A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. *Cancer Research*, **2003**, 63, 5462-9	10.1	166
350	Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. *Journal of Biological Chemistry*, **2000**, 275, 6868-75	5.4	164

349	Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. *Clinical Cancer Research*, **2006**, 12, 7261-70	12.9	163
348	Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. *Journal of Carcinogenesis*, **2008**, 7, 9	1.9	160
347	MET as a possible target for non-small-cell lung cancer. *Journal of Clinical Oncology*, **2013**, 31, 1089-96	2.2	152
346	Ethnic differences and functional analysis of MET mutations in lung cancer. *Clinical Cancer Research*, **2009**, 15, 5714-23	12.9	151
345	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. *Cancer Cell*, **2020**, 38, 79-96.e11	24.3	145
344	Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. *Journal of Biological Chemistry*, **2002**, 277, 7875-81	5.4	143
343	Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. *Journal of Clinical Oncology*, **2008**, 26, 870-6	2.2	142
342	Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. *Gynecologic Oncology*, **2008**, 110, 49-55	4.9	141
341	c-Met is a potentially new therapeutic target for treatment of human melanoma. *Clinical Cancer Research*, **2007**, 13, 2246-53	12.9	141
340	AXL mediates resistance to cetuximab therapy. *Cancer Research*, **2014**, 74, 5152-64	10.1	140
339	Molecular pathways and therapeutic targets in lung cancer. *Oncotarget*, **2014**, 5, 1392-433	3.3	135
338	The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. *PLoS ONE*, **2014**, 9, e91577	3.7	132
337	Phase II study of imatinib in patients with small cell lung cancer. *Clinical Cancer Research*, **2003**, 9, 5880-7	12.9	124
336	The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. *Trends in Cancer*, **2018**, 4, 110-118	12.5	123
335	The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. *Journal of Biological Chemistry*, **1996**, 271, 31222-6	5.4	116
334	A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. *Cancer Research*, **2007**, 67, 3529-34	10.1	114
333	A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. *Clinical Cancer Research*, **2005**, 11, 2312-9	12.9	114
332	The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. *Journal of Biological Chemistry*, **1999**, 274, 36684-92	5.4	111

331	c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. *Current Oncology Reports*, **2007**, 9, 102-8	6.3	107
330	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. *Journal of Thoracic Oncology*, **2016**, 11, 453-74	8.9	106
329	MET as a target for treatment of chest tumors. *Lung Cancer*, **2009**, 63, 169-79	5.9	105
328	p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. *Journal of Biological Chemistry*, **1996**, 271, 25198-203	5.4	104
327	Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. *Journal of Thoracic Oncology*, **2015**, 10, S1-63	8.9	102
326	Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. *Cancer Letters*, **2016**, 380, 494-504	9.9	102
325	Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation. *Nature Clinical Practice Oncology*, **2006**, 3, 50-7; quiz 1 p following 57		102
324	CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. *Journal of Biological Chemistry*, **2007**, 282, 30643-57	5.4	102
323	Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. *Journal of Biological Chemistry*, **1997**, 272, 4230-6	5.4	98
322	CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. *Journal of Biological Chemistry*, **1995**, 270, 29145-50	5.4	97
321	Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. *Cancer Research*, **2008**, 68, 132-42	10.1	96
320	Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. *Journal of Clinical Oncology*, **2014**, 32, 2328-34	2.2	95
319	Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. *Cytokine and Growth Factor Reviews*, **1997**, 8, 63-79	17.9	95
318	Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. *Cancer Discovery*, **2011**, 1, 573-9	24.4	94
317	The role of the c-Met pathway in lung cancer and the potential for targeted therapy. *Therapeutic Advances in Medical Oncology*, **2011**, 3, 171-84	5.4	93
316	MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. *Molecular Cancer Therapeutics*, **2017**, 16, 555-565	6.1	92
315	Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. *JAMA Oncology*, **2016**, 2, 805-12	13.4	92
314	Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. *Cancer Research*, **2002**, 62, 5242-7	10.1	92

313	Lung cancer-a fractal viewpoint. *Nature Reviews Clinical Oncology*, **2015**, 12, 664-75	19.4	91
312	Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America: recommendations of The American Association for Thoracic Surgery Task Force for Lung Cancer Screening and Surveillance. *Journal of Thoracic and Cardiovascular Surgery*, **2012**, 144, 25-32	1.5	89
311	Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 376-81	8.9	88
310	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. *Oncologist*, **2016**, 21, 762-70	5.7	87
309	CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. *PLoS ONE*, **2010**, 5, e8972	3.7	85
308	EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. *Journal of Biological Chemistry*, **2010**, 285, 18575-85	5.4	84
307	A novel classification of lung cancer into molecular subtypes. *PLoS ONE*, **2012**, 7, e31906	3.7	82
306	Steel factor induces tyrosine phosphorylation of CRKL and binding of CRKL to a complex containing c-kit, phosphatidylinositol 3-kinase, and p120(CBL). *Journal of Biological Chemistry*, **1997**, 272, 10248-53	5.4	81
305	Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). *Journal of Biological Chemistry*, **1997**, 272, 14320-6	5.4	80
304	A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. *Clinical Cancer Research*, **2007**, 13, 515-22	12.9	80
303	A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. *Advances in Experimental Medicine and Biology*, **2014**, 799, 85-117	3.6	76
302	The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. *Journal of Biological Chemistry*, **1997**, 272, 33373-6	5.4	75
301	PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. *Laboratory Investigation*, **2009**, 89, 301-14	5.9	74
300	Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. *Oncogene*, **1999**, 18, 67-77	9.2	74
299	RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. *Cancer Biology and Therapy*, **2011**, 12, 9-46	4.6	72
298	AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. *Clinical Cancer Research*, **2015**, 21, 2601-12	12.9	71
297	The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. *Oncogene*, **1997**, 15, 2379-84	9.2	71
296	Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. *Journal of Thoracic Oncology*, **2010**, 5, 2044-6	8.9	69

295	FYN is overexpressed in human prostate cancer. *BJU International*, **2009**, 103, 171-7	5.6	68
294	Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. *Anticancer Research*, **2004**, 24, 1031-8	2.3	68
293	Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. *Clinical Cancer Research*, **2011**, 17, 5257-67	12.9	67
292	FAK and paxillin, two potential targets in pancreatic cancer. *Oncotarget*, **2016**, 7, 31586-601	3.3	67
291	Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. *Cancer Research*, **2009**, 69, 7538-47	10.1	63
290	B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. *Cell*, **2018**, 173, 470-484.e18	56.2	62
289	Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. *Clinical Cancer Research*, **2014**, 20, 6336-45	12.9	61
288	Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. *Cancer Chemotherapy and Pharmacology*, **2008**, 61, 549-58	3.5	61
287	The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. *Journal of Biological Chemistry*, **2000**, 275, 1405-13	5.4	60
286	The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. *Clinical and Translational Medicine*, **2019**, 8, 9	5.7	58
285	The Mitochondrion as an Emerging Therapeutic Target in Cancer. *Trends in Molecular Medicine*, **2020**, 26, 119-134	11.5	57
284	Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. *Journal of Biological Chemistry*, **2014**, 289, 13476-91	5.4	56
283	Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. *Journal of Thoracic Oncology*, **2008**, 3, 1003-11	8.9	54
282	Molecular and cellular biology of small cell lung cancer. *Seminars in Oncology*, **2003**, 30, 57-71	5.5	54
281	Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. *Cancer Biology and Therapy*, **2018**, 19, 316-327	4.6	53
280	Tyrosine kinase mutations in human cancer. *Current Molecular Medicine*, **2007**, 7, 77-84	2.5	53
279	Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. *Clinical Cancer Research*, **2014**, 20, 1666-75	12.9	52
278	Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2011**, 6, 1418-25	8.9	51

277	Role of focal adhesion proteins in signal transduction and oncogenesis. *Critical Reviews in Oncogenesis*, **1997**, 8, 343-58	1.3	50
276	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *Journal of Thoracic Oncology*, **2013**, 13, 1655-1667	8.9	50
275	MET molecular mechanisms and therapies in lung cancer. *Cell Adhesion and Migration*, **2010**, 4, 146-52	3.2	49
274	The role of chemokine receptor CXCR4 in lung cancer. *Cancer Biology and Therapy*, **2010**, 9, 409-16	4.6	49
273	Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. *Clinical Cancer Research*, **2004**, 10, 3020-8	12.9	48
272	Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. *Oncotarget*, **2016**, 7, 66880-66891	3.3	48
271	Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. *Clinical Cancer Research*, **2015**, 21, 4321-6	12.9	47
270	Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. *Mass Spectrometry Reviews*, **2007**, 26, 451-66	11	47
269	SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL. *Journal of Biological Chemistry*, **2001**, 276, 2451-8	5.4	47
268	Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. *Cancer Research*, **2014**, 74, 884-95	10.1	46
267	Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2007**, 292, L1488-94	5.8	46
266	MET pathway as a therapeutic target. *Journal of Thoracic Oncology*, **2009**, 4, 444-7	8.9	45
265	The role of EGFR inhibition in the treatment of non-small cell lung cancer. *Oncologist*, **2009**, 14, 1116-30	5.7	44
264	A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. *Journal of Biological Chemistry*, **2002**, 277, 20887-94	5.4	44
263	The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. *PLoS ONE*, **2013**, 8, e67668	3.7	43
262	Role of MetMAb (OA-5D5) in c-MET active lung malignancies. *Expert Opinion on Biological Therapy*, **2011**, 11, 1655-62	5.4	43
261	Role of c-Met in cancer: emphasis on lung cancer. *Seminars in Oncology*, **2009**, 36, S52-8	5.5	43
260	CD2 molecules redistribute to the uropod during T cell scanning: implications for cellular activation and immune surveillance. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 7582-7	11.5	42

259	MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. *PLoS ONE*, **2014**, 9, e105919	3.7	42
258	Lung carcinoma in African Americans. *Nature Clinical Practice Oncology*, **2007**, 4, 118-29		41
257	2-methoxyestradiol alters cell motility, migration, and adhesion. *Blood*, **2003**, 102, 289-96	2.2	41
256	Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 1356-68	6.1	40
255	Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. *Cancer*, **2011**, 117, 3889-99	6.4	40
254	Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. *Cancer Research*, **2011**, 71, 2423-7	10.1	40
253	Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. *Oncologist*, **2003**, 8, 69-75	5.7	40
252	ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6919-24	11.5	40
251	Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. *Cancer Research*, **2013**, 73, 184-94	10.1	36
250	PAX6 is expressed in pancreatic cancer and actively participates in cancer progression through activation of the MET tyrosine kinase receptor gene. *Journal of Biological Chemistry*, **2009**, 284, 27524-32	5.4	36
249	Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease. *Journal of Clinical Pathology*, **2011**, 64, 16-24	3.9	36
248	Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. *Leukemia and Lymphoma*, **1997**, 28, 65-72	1.9	36
247	Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. *Cancer Research*, **2005**, 65, 5301-9	10.1	36
246	Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. *Oncotarget*, **2016**, 7, 13621-33	3.3	36
245	Quality of life after radical pleurectomy decortication for malignant pleural mesothelioma. *Annals of Thoracic Surgery*, **2012**, 94, 1086-92	2.7	35
244	Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. *Journal of Biological Chemistry*, **2010**, 285, 32596-605	5.4	35
243	Molecular cloning and characterization of human trabeculin-alpha, a giant protein defining a new family of actin-binding proteins. *Journal of Biological Chemistry*, **1999**, 274, 33522-30	5.4	35
242	Thrombopoietin induces activation of the phosphatidylinositol-3' kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. *Journal of Cellular Physiology*, **1997**, 171, 28-33	7	34

241	MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. *Journal of Environmental Pathology, Toxicology and Oncology*, **2009**, 28, 89-98	2.1	34
240	A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. *Lung Cancer*, **2017**, 105, 7-13	5.9	33
239	Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. *European Urology*, **2018**, 74, 124-128	10.2	33
238	Personalized treatment of lung cancer. *Seminars in Oncology*, **2011**, 38, 274-83	5.5	33
237	Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 856-65	8.9	33
236	State-of-the-art considerations in small cell lung cancer brain metastases. *Oncotarget*, **2017**, 8, 71223-71233	3.3	33
235	Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. *Archives of Pathology and Laboratory Medicine*, **2010**, 134, 1702-5	5	33
234	The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. *Science Signaling*, **2017**, 10,	8.8	32
233	Differential expression of RON in small and non-small cell lung cancers. *Genes Chromosomes and Cancer*, **2012**, 51, 841-51	5	31
232	The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. *Cancer Treatment Reviews*, **2020**, 87, 102022	14.4	30
231	Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. *Molecular Cancer Therapeutics*, **2016**, 15, 2175-86	6.1	30
230	Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. *Journal of Biological Chemistry*, **2014**, 289, 24043-58	5.4	30
229	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. *Oncotarget*, **2017**, 8, 42198-42213	3.3	30
228	Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. *Cancer Biology and Therapy*, **2013**, 14, 679-91	4.6	30
227	Value-based genomics. *Oncotarget*, **2018**, 9, 15792-15815	3.3	30
226	Notch signaling in breast cancer: From pathway analysis to therapy. *Cancer Letters*, **2019**, 461, 123-131	9.9	29
225	Critical role of S1PR1 and integrin # in HGF/c-Met-mediated increases in vascular integrity. *Journal of Biological Chemistry*, **2013**, 288, 2191-200	5.4	29
224	Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. *Cellular Signalling*, **2007**, 19, 2329-38	4.9	29

223	The MET axis as a therapeutic target. *Update on Cancer Therapeutics*, **2009**, 3, 109-118		28
222	C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. *Cancer Biology and Therapy*, **2008**, 7, 856-63	4.6	28
221	Receptor tyrosine kinases and inhibitors in lung cancer. *Scientific World Journal, The*, **2004**, 4, 589-604	2.2	28
220	Involvement of the adapter protein CRKL in integrin-mediated adhesion. *Oncogene*, **1999**, 18, 3343-53	9.2	28
219	Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma. *Scientific Reports*, **2016**, 6, 24578	4.9	27
218	Mitochondrial dynamics: biology and therapy in lung cancer. *Expert Opinion on Investigational Drugs*, **2014**, 23, 675-92	5.9	27
217	Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunity. *Clinical Cancer Research*, **2008**, 14, 3896-905	12.9	27
216	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. *Respirology*, **2006**, 11, 687-92	3.6	27
215	Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. *Cancer Chemotherapy and Pharmacology*, **2001**, 48, 151-9	3.5	27
214	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). *Cell Reports Medicine*, **2021**, 2, 100186	18	27
213	A review of topoisomerase inhibition in lung cancer. *Cancer Biology and Therapy*, **2006**, 5, 1600-7	4.6	26
212	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. *Journal of Thoracic Oncology*, **2021**, 16, 1030-1041	8.9	26
211	TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. *Cancer Science*, **2017**, 108, 488-496	6.9	25
210	Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention. *European Journal of Oncology Nursing*, **2017**, 29, 125-134	2.8	25
209	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. *Targeted Oncology*, **2012**, 7, 199-210	5	25
208	Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. *Journal of Clinical Oncology*, **2013**, 31, e254-8	2.2	25
207	An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. *Cancer*, **2011**, 117, 5344-50	6.4	25
206	Review of clinic trials: agents targeting c-Met. *Reviews on Recent Clinical Trials*, **2007**, 2, 143-7	1.2	25

205	Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer. *Cell Communication and Signaling*, **2019**, 17, 167	7.5	25
204	Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. *Clinical Cancer Research*, **2011**, 17, 3112-22	12.9	24
203	Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. *Anticancer Research*, **2003**, 23, 49-62	2.3	24
202	Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. *Investigational New Drugs*, **2017**, 35, 334-344	4.3	23
201	EphB4 as a therapeutic target in mesothelioma. *BMC Cancer*, **2013**, 13, 269	4.8	23
200	Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. *Oncogene*, **2002**, 21, 1423-33	9.2	23
199	Managing Patients With Relapsed Small-Cell Lung Cancer. *Journal of Oncology Practice*, **2018**, 14, 359-366	3.1	23
198	Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. *Seminars in Oncology*, **2018**, 45, 210-219	5.5	23
197	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1-Line Treatment for Non-Small-Cell Lung Cancer. *Molecular Therapy - Oncolytics*, **2019**, 13, 1-6	6.4	22
196	A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors. *Molecular Cancer Therapeutics*, **2015**, 14, 461-9	6.1	22
195	Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. *Oncotarget*, **2018**, 9, 19793-19806	3.3	22
194	c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 308, L1025-38	5.8	21
193	SOX9: The master regulator of cell fate in breast cancer. *Biochemical Pharmacology*, **2020**, 174, 113789	6	21
192	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. *Oncotarget*, **2017**, 8, 67639-67650	3.3	20
191	Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. *Cancer Medicine*, **2014**, 3, 681-92	4.8	20
190	Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. *Oncotarget*, **2016**, 7, 18876-86	3.3	20
189	Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. *Expert Review of Molecular Diagnostics*, **2016**, 16, 737-49	3.8	20
188	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. *Clinical and Translational Medicine*, **2018**, 7, 32	5.7	20

187	Loss of H2B monoubiquitination is associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. *International Journal of Cancer*, **2017**, 141, 766-777	7.5	19
186	HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression. *Frontiers in Oncology*, **2015**, 5, 164	5.3	19
185	Lack of association of C-Met-N375S sequence variant with lung cancer susceptibility and prognosis. *International Journal of Medical Sciences*, **2013**, 10, 988-94	3.7	19
184	MET and phosphorylated MET as potential biomarkers in lung cancer. *Journal of Environmental Pathology, Toxicology and Oncology*, **2011**, 30, 341-54	2.1	19
183	EGFR-targeted therapeutics: focus on SCCHN and NSCLC. *Scientific World Journal, The*, **2008**, 8, 909-19	2.2	19
182	Tumor Heterogeneity and Therapeutic Resistance. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e585-93	7.1	19
181	PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma. *Scientific Reports*, **2016**, 6, 32992	4.9	18
180	2'-Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76. *Molecular Carcinogenesis*, **2018**, 57, 1751-1762	5	18
179	Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides. *Cancer Letters*, **2014**, 343, 14-23	9.9	18
178	Geographic variation in radiologist capacity and widespread implementation of lung cancer CT screening. *Journal of Medical Screening*, **2014**, 21, 207-15	1.4	18
177	DIFFERENTIAL SERUM LEVEL OF SPECIFIC HAPTOGLOBIN ISOFORMS IN SMALL CELL LUNG CANCER. *Current Proteomics*, **2010**, 7, 49-65	0.7	18
176	Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. *ImmunoTargets and Therapy*, **2012**, 2012, 7-12	9	18
175	Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach. *Future Oncology*, **2015**, 11, 489-500	3.6	17
174	PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. *Journal of Biological Chemistry*, **2015**, 290, 21901-14	5.4	17
173	RNA-based therapies: A cog in the wheel of lung cancer defense. *Molecular Cancer*, **2021**, 20, 54	42.1	17
172	Role played by paxillin and paxillin tyrosine phosphorylation in hepatocyte growth factor/sphingosine-1-phosphate-mediated reactive oxygen species generation, lamellipodia formation, and endothelial barrier function. *Pulmonary Circulation*, **2015**, 5, 619-30	2.7	16
171	Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. *Scientific Reports*, **2015**, 5, 10641	4.9	16
170	Integrin-dependent protein tyrosine phosphorylation is a key regulatory event in collagen-IV-mediated adhesion and proliferation of human lung tumor cell line, Calu-1. *Annals of Thoracic Surgery*, **2004**, 78, 450-7	2.7	16

169	Lymphatic vessel density is not associated with lymph node metastasis in non-small cell lung carcinoma. *Archives of Pathology and Laboratory Medicine*, **2008**, 132, 1882-8	5	16
168	A new PET/CT volumetric prognostic index for non-small cell lung cancer. *Lung Cancer*, **2015**, 89, 43-9	5.9	15
167	Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 576-84	6.1	15
166	Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. *Oncotarget*, **2017**, 8, 43733-43751	3.3	15
165	2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer. *Oncotarget*, **2018**, 9, 18053-18068	3.3	15
164	Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. *Anticancer Research*, **2003**, 23, 3379-96	2.3	15
163	Untying the gordion knot of targeting MET in cancer. *Cancer Treatment Reviews*, **2018**, 66, 95-103	14.4	14
162	Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. *Journal of Thoracic Oncology*, **2011**, 6, 786-9	8.9	14
161	Case 1: small bowel obstruction due to metastatic lung cancer. *Journal of Clinical Oncology*, **2000**, 18, 227-8	2.2	14
160	Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. *Cureus*, **2016**, 8, e513	1.2	14
159	Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors. *Molecular Cancer Therapeutics*, **2020**, 19, 1210-1217	6.1	13
158	Therapeutic targeting of the receptor tyrosine kinase Met. *Cancer Treatment and Research*, **2004**, 119, 121-38	3.5	13
157	Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting **2018**, 4, 49-54		13
156	Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. *Journal of Clinical Medicine*, **2019**, 8,	5.1	12
155	Small cell lung cancer: from molecular biology to novel therapeutics. *Journal of Experimental Therapeutics and Oncology*, **2003**, 3, 305-18	0.8	12
154	AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. *Clinical Cancer Research*, **2020**, 26, 4349-4359	12.9	12
153	Tumor Heterogeneity and Therapeutic Resistance. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, e585-e593	7.1	12
152	Targeted Therapies in Non-small-Cell Lung Cancer. *Cancer Treatment and Research*, **2019**, 178, 3-43	3.5	11

151	Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. *Lung Cancer*, **2019**, 133, 136-143	5.9	11
150	Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level. *Biomolecules*, **2019**, 9,	5.9	11
149	Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL. *Scientific Reports*, **2017**, 7, 9192	4.9	11
148	Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. *Seminars in Cancer Biology*, **2020**,	12.7	11
147	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. *Cancers*, **2020**, 12,	6.6	11
146	EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. *Oncogenesis*, **2019**, 8, 49	6.6	10
145	RLIP inhibition suppresses breast-to-lung metastasis. *Cancer Letters*, **2019**, 447, 24-32	9.9	10
144	A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. *Expert Opinion on Drug Safety*, **2015**, 14, 485-93	4.1	10
143	Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2015**, 11, 1971-4	6	10
142	Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. *Frontiers in Oncology*, **2020**, 10, 593	5.3	10
141	Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. *Case Reports in Clinical Pathology*, **2014**, 1, 151-154	0.1	10
140	Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. *BMC Cancer*, **2014**, 14, 185	4.8	10
139	Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. *Journal of Clinical Oncology*, **2003**, 21, 2437-8	2.2	10
138	Altered membrane fluidity in rat hepatocytes during endotoxic shock. *Molecular and Cellular Biochemistry*, **1993**, 121, 143-8	4.2	10
137	Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC).. *Journal of Clinical Oncology*, **2019**, 37, TPS8577-TPS8577	2.2	10
136	Crizotinib (PF02341066) as a ALK /MET inhibitor- Special Emphasis as a Therapeutic Drug Against Lung Cancer. *Drugs of the Future*, **2011**, 36, 91-99	2.3	10
135	Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. *Oncotarget*, **2018**, 9, 26226-26242	3.3	10
134	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. *Cancer Treatment Reviews*, **2017**, 55, 181-189	14.4	9

133	Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. *Molecular Carcinogenesis*, **2019**, 58, 1438-1449	5	9
132	RLIP: An existential requirement for breast carcinogenesis. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2019**, 1871, 281-288	11.2	9
131	Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. *Journal of Thoracic Disease*, **2020**, 12, 5086-5095	2.6	9
130	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. *Journal of Clinical Medicine*, **2020**, 9,	5.1	9
129	MET receptor in oncology: From biomarker to therapeutic target. *Advances in Cancer Research*, **2020**, 147, 259-301	5.9	9
128	EphB4: A promising target for upper aerodigestive malignancies. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1869, 128-137	11.2	9
127	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. *Journal of Thoracic Oncology*, **2019**, 14, 1718-1731	8.9	9
126	Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. *CNS Oncology*, **2014**, 3, 61-75	4	9
125	Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. *Clinical Lung Cancer*, **2012**, 13, 123-8	4.9	9
124	Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). *Journal of Thoracic Oncology*, **2011**, 6, 1741-5	8.9	9
123	Protein kinase C beta in malignant pleural mesothelioma. *Anti-Cancer Drugs*, **2008**, 19, 841-8	2.4	9
122	2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells. *Journal of Proteomics*, **2019**, 192, 233-245	3.9	9
121	Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. *Cancer Biology and Therapy*, **2018**, 19, 1023-1032	4.6	9
120	Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2'-Hydroxyflavanone. *Cancer Letters*, **2018**, 438, 144-153	9.9	9
119	A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors. *Cancer Chemotherapy and Pharmacology*, **2018**, 82, 309-317	3.5	9
118	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. *Magnetic Resonance Imaging*, **2020**, 69, 49-56	3.3	8
117	Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. *Growth Factors*, **2014**, 32, 202-6	1.6	8
116	Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. *Journal of Clinical Bioinformatics*, **2011**, 1, 1-11		8

115	Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2007**, 30, 258-63	2.7	8
114	Genomic mutation-driven metastatic breast cancer therapy: a single center experience. *Oncotarget*, **2017**, 8, 26414-26423	3.3	8
113	Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). *Cancers*, **2020**, 13,	6.6	8
112	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. *Journal of Clinical Medicine*, **2018**, 7,	5.1	8
111	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. *Future Oncology*, **2016**, 12, 1045-58	3.6	7
110	Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma. *Journal of Clinical Oncology*, **2011**, 29, e598-600	2.2	7
109	Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. *Cancer*, **1994**, 74, 1887-90	6.4	7
108	A Non-genetic Mechanism Involving the Integrin β1/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. *IScience*, **2020**, 23, 101496	6.1	7
107	Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics. *Journal of Biological Chemistry*, **2020**, 295, 13393-13406	5.4	7
106	Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. *Oncologist*, **2021**, 26, 1052-1061	5.7	7
105	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. *Chest*, **2021**, 160, 1095-1107	5.3	7
104	Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin. *Journal of Molecular Biology*, **2015**, 427, 2532-2547	6.5	6
103	Therapeutic targeting of miRNA-216b in cancer. *Cancer Letters*, **2020**, 484, 16-28	9.9	6
102	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. *Future Oncology*, **2020**, 16, 4289-4301	3.6	6
101	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. *Journal of Thoracic Oncology*, **2019**, 14, 1704-1717	8.9	6
100	Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. *Journal of Clinical Medicine*, **2019**, 8,	5.1	6
99	Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2015**, 38, 442-7	2.7	6
98	Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. *Journal of Thoracic Oncology*, **2012**, 7, S372-4	8.9	6

97	Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. *Journal of Thoracic Oncology*, **2011**, 6, S1810-1	8.9	6
96	Novel targets for therapeutic agents in small cell lung cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2004**, 2, 165-72	7.3	6
95	Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring exon 14 mutation: a research report. *Journal of Physical Education and Sports Management*, **2020**, 6,	2.8	6
94	Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. *Journal of Clinical Medicine*, **2020**, 9,	5.1	6
93	-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. *Biomedicines*, **2020**, 8,	4.8	6
92	Group Behavior and Emergence of Cancer Drug Resistance. *Trends in Cancer*, **2021**, 7, 323-334	12.5	6
91	Infectious complications of immune checkpoint inhibitors in solid organ malignancies. *Cancer Medicine*, **2021**,	4.8	6
90	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. *Lung Cancer*, **2020**, 146, 174-181	5.9	5
89	The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. *Future Oncology*, **2018**, 14, 1897-1908	3.6	5
88	Effective osimertinib treatment in a patient with discordant T790M mutation detection between liquid biopsy and tissue biopsy. *BMC Cancer*, **2018**, 18, 314	4.8	5
87	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. *Oncotarget*, **2017**, 8, 18726-18734	3.3	5
86	Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. *Journal of Neurology Research*, **2012**, 2, 1-9	2.5	5
85	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. *Nature Communications*, **2021**, 12, 3039	17.4	5
84	Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2019**, 42, 337-344	2.7	5
83	USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. *Molecular Cancer Research*, **2020**, 18, 424-435	6.6	5
82	ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy. *Journal of Clinical Neuroscience*, **2015**, 22, 1978-9	2.2	4
81	Precision medicine and actionable alterations in lung cancer: A single institution experience. *PLoS ONE*, **2020**, 15, e0228188	3.7	4
80	Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 963-966	2.7	4

79	Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib. *Journal of Clinical Pharmacology*, **2019**, 59, 1632-1640	2.9	4
78	Generation of comprehensive thoracic oncology database--tool for translational research. *Journal of Visualized Experiments*, **2011**,	1.6	4
77	Benefit of active treatment in non-small-cell lung cancer in elderly patients and patients with poor performance status. *Clinical Lung Cancer*, **2003**, 5, 86-9	4.9	4
76	The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. *Oncotarget*, **2020**, 11, 1953-1960	3.3	4
75	Presence and structure-activity relationship of intrinsically disordered regions across mucins. *FASEB Journal*, **2020**, 34, 1939-1957	0.9	4
74	The DNA walk and its demonstration of deterministic chaos-relevance to genomic alterations in lung cancer. *Bioinformatics*, **2019**, 35, 2738-2748	7.2	4
73	Targeting RLIP with CRISPR/Cas9 controls tumor growth. *Carcinogenesis*, **2021**, 42, 48-57	4.6	4
72	The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. *Clinical Lung Cancer*, **2021**, 22, e84-e97	4.9	4
71	Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer. *Journal of Oncology Practice*, **2018**, 14, 569-571	3.1	4
70	c-Met inhibition. *Clinical Advances in Hematology and Oncology*, **2006**, 4, 823-4	0.6	4
69	Intrinsically Disordered Proteins: Critical Components of the Wetware.. *Chemical Reviews*, **2022**,	68.1	4
68	Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy.. *Biomolecules*, **2021**, 12,	5.9	4
67	Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer. *Oncology Letters*, **2017**, 13, 4027-4034	2.6	3
66	Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
65	C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. *Cancer Biology and Therapy*, **2016**, 17, 91-103	4.6	3
64	Value-Based Medicine and Integration of Tumor Biology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 833-840	7.1	3
63	Activating the expression of human K-rasG12D stimulates oncogenic transformation in transgenic goat fetal fibroblast cells. *PLoS ONE*, **2014**, 9, e90059	3.7	3
62	Heuristic value-based framework for lung cancer decision-making. *Oncotarget*, **2018**, 9, 29877-29891	3.3	3

61	Suppressing chemoresistance in lung cancer via dynamic phenotypic switching and intermittent therapy		3
60	RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2020**, 1873, 188337	11.2	3
59	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. *IScience*, **2020**, 23, 101692	6.1	3
58	Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. *Frontiers in Oncology*, **2021**, 11, 621088	5.3	3
57	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. *Cureus*, **2021**, 13, e16266	1.2	3
56	JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted -Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. *JTO Clinical and Research Reports*, **2021**, 2, 100103	1.4	3
55	Targeting the mercapturic acid pathway for the treatment of melanoma. *Cancer Letters*, **2021**, 518, 10-22	9.9	3
54	Early mortality of stage IV non-small cell lung cancer in the United States. *Acta Oncologica*, **2019**, 58, 1095-1101	3.2	2
53	Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. *Journal of Clinical Medicine*, **2019**, 8,	5.1	2
52	Three-dimensional stereoscopic volume rendering of malignant pleural mesothelioma. *International Surgery*, **2012**, 97, 65-70	0.1	2
51	Novel Transforming Mutations of CBL in Human Acute Myeloid Leukemia. *Blood*, **2008**, 112, 2948-2948	2.2	2
50	Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).. *Journal of Clinical Oncology*, **2020**, 38, TPS9080-TPS9080	2.2	2
49	Value-Based Medicine and Integration of Tumor Biology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 833-840	7.1	2
48	Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.. *Journal of Clinical Oncology*, **2019**, 37, 9093-9093	2.2	2
47	Germline mutations and age at onset of lung adenocarcinoma. *Cancer*, **2021**, 127, 2801-2806	6.4	2
46	ST6GalNAc-I promotes lung cancer metastasis by altering MUC5AC sialylation. *Molecular Oncology*, **2021**, 15, 1866-1881	7.9	2
45	Opportunities for improving cancer treatment using systems biology. *Current Opinion in Systems Biology*, **2019**, 17, 41-50	3.2	2
44	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. *JCO Oncology Practice*, **2021**, 17, e257-e265	2.3	2

43	RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. *Carcinogenesis*, **2021**, 42, 742-752	4.6	2
42	Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey. *JCO Oncology Practice*, **2021**, 17, e1120-e1130	2.3	2
41	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. *Journal of Clinical Medicine*, **2020**, 9,	5.1	1
40	Association of Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case-Control Studies *Cancers*, **2020**, 12,	6.6	1
39	Etoposide and Temozolomide in Combination for the Treatment of Progressive Small-Cell Lung Cancer Central Nervous System Metastases: Two Cases. *Tumori*, **2013**, 99, e73-e76	1.7	1
38	Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).. *Journal of Clinical Oncology*, **2015**, 33, 7567-7567	2.2	1
37	Co-opting disorder into order: Intrinsically disordered proteins and the early evolution of complex multicellularity.. *International Journal of Biological Macromolecules*, **2022**, 201, 29-36	7.9	1
36	A Non-genetic Mechanism for Chemoresistance in Lung Cancer: The Role of Integrin /Paxillin Axis		1
35	Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. *International Journal of Oncology*, **2020**, 57, 80-86	4.4	1
34	Disparate outcomes in nonsmall cell lung cancer by immigration status. *Cancer Medicine*, **2021**, 10, 2660-2667	4.8	1
33	Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). *British Journal of Cancer*, **2021**, 125, 582-592	8.7	1
32	Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma. *Clinical Lung Cancer*, **2021**,	4.9	1
31	Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions. *Cancers*, **2021**, 13,	6.6	1
30	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. *Molecular Cancer Therapeutics*, **2021**, 20, 1820-1835	6.1	1
29	Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. *BMC Cancer*, **2016**, 16, 568	4.8	1
28	Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
27	Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma. *Biophysics Reviews*, **2022**, 3, 011306	2.6	1
26	Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.. *Frontiers in Pharmacology*, **2021**, 12, 806570	5.6	0

25	Protein conformational dynamics and phenotypic switching.. *Biophysical Reviews*, **2021**, 13, 1127-1138	3.7	0
24	Activating p53 function by targeting RLIP. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1875, 188512	11.2	0
23	The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin -Like 1--Catenin Protein Complex. *Journal of Pharmacology and Experimental Therapeutics*, **2021**, 378, 77-86	4.7	0
22	The Association between Polluted Neighborhoods and -Mutated Non-Small Cell Lung Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1498-1505	4	0
21	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. *Clinical Colorectal Cancer*, **2021**, 20, e129-e138	3.8	0
20	Prevention of mammary carcinogenesis in MMTV-neu mice by targeting RLIP. *Molecular Carcinogenesis*, **2021**, 60, 213-223	5	0
19	Co-stimulatory and co-inhibitory immune markers in solid tumors with alterations. *Future Science OA*, **2020**, 7, FSO662	2.7	0
18	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. *Clinical Lung Cancer*, **2021**, 22, e703-e707	4.9	0
17	Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non-Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy. *Clinical Lung Cancer*, **2021**, 22, e678-e683	4.9	0
16	AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.. *BMC Cancer*, **2022**, 22, 447	4.8	0
15	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. *Journal of Thoracic Disease*, **2020**, 12, 5096-5103	2.6	
14	A new hope for precision medicine. *Science Translational Medicine*, **2013**, 5, 208fs38	17.5	
13	Response. *Chest*, **2021**, 160, e375-e376	5.3	
12	Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non-small Cell Lung Cancer and Malignant Mesothelioma. *FASEB Journal*, **2018**, 32, 835.9	0.9	
11	MET as a Therapeutic Target: Have Clinical Outcomes Been MET in Lung Cancer?. *Current Cancer Research*, **2019**, 101-123	0.2	
10	Lung cancer in African-Americans and analysis of estrogen plus progestin use.. *Journal of Clinical Oncology*, **2019**, 37, e18258-e18258	2.2	
9	NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms.. *Blood*, **2009**, 114, 2190-2190	2.2	
8	Phenotypic switching and prostate diseases: a model proposing a causal link between benign prostatic hyperplasia and prostate cancer **2020**, 569-589		

List of Publications

7	Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic. *Kidney Cancer*, **2021**, 5, 73-78	0.6
6	Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?. *JCO Oncology Practice*, **2021**, 17, 52-53	2.3
5	p53 and Bcl-2 in small cell-lung cancer. *Clinical Lung Cancer*, **2003**, 4, 303	4.9
4	Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188	
3	Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188	
2	Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188	
1	Precision medicine and actionable alterations in lung cancer: A single institution experience **2020**, 15, e0228188	